Great to see the DEA are getting on board and have upped their...

Great to see the DEA are getting on board and have upped their production quotas for next year, further legitimising and derisking the sector -

"The Drug Enforcement Administration (DEA) has released its final 2023 production quotas for drugs to be used in research—and the agency is now calling for even more manufacturing of psychedelic compounds like MDMA, psilocyn and 5-MeO-DMT than the existing significant increases it had initially proposed for next year."

“DEA is committed to ensuring an adequate and uninterrupted supply of controlled substances in order to meet the estimated legitimate medical, scientific, research, and industrial needs of the U.S., for lawful export requirements, and for the establishment and maintenance of reserve stocks,”

"For marijuana, DEA also boosted the production quota in the initial 2023 proposal, saying it wants to see 6.7 million grams (or 14,770 pounds) of cannabis grown next year to meet those medical and scientific demands."

To put marijuana into perspective - "The agency’s final marijuana quota for 2022 was 3.2 million grams, and it was 2 million grams for 2021."



I think psilocybin has been left off this table as there is no change from last to this year at 8000 grams.

https://www.marijuanamoment.net/dea-proposes-even-higher-2023-production-quotas-for-psychedelics-like-mdma-and-psilocyn/

https://www.federalregister.gov/documents/2022/12/02/2022-26351/established-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and-assessment